Cox proportional hazards models for mortality of CLL patients with VTE compared with CLL patients with no VTE after the CLL diagnosis
| . | HR, crude (95% CI) . | HR, multivariable (95% CI)* . |
|---|---|---|
| Sex | ||
| Female | 2.76 (1.46-5.21) | 2.06 (1.07-3.95) |
| Male | 1.83 (1.03-3.26) | 2.40 (1.34-4.32) |
| Age, y | ||
| ≤60 | 17.41 (5.73-52.90) | 7.74 (2.12-28.29) |
| >60 to ≤70 | 1.14 (0.36-3.61) | 1.59 (0.50-5.14) |
| >70 to ≤80 | 1.35 (0.50-3.64) | 1.00 (0.36-2.78) |
| >80 | 2.65 (1.45-4.88) | 2.74 (1.48-5.08) |
| WHO-PF | ||
| 0-1 | 2.51 (1.63-3.48) | 2.62 (1.69-4.04) |
| >1 | ND | ND |
| Previous VTE | ||
| No | 2.36 (1.49-3.74) | 2.37 (1.50-3.76) |
| Yes | 1.05 (0.32-3.48) | 1.10 (0.32-3.83) |
| Second primary cancer | ||
| No | 1.68 (0.9-2.85) | 1.40 (0.82-2.39) |
| Yes | ND | ND |
| IgHV mutational status | ||
| Mutated | 2.11 (0.93-4.75) | 1.75 (0.76-4.02) |
| Unmutated | 2.07 (0.97-4.43) | 1.77 (0.82-3.81) |
| Not assessed | ||
| β2-microglobulin, mg/L | ||
| <4 | 2.02 (1.07-3.80) | 2.21 (1.16-4.21) |
| ≥4 | 1.44 (0.49-2.68) | 1.72 (0.73-4.04) |
| Not assessed | 2.89 (1.28-6.53) | 1.98 (0.85-4.60) |
| . | HR, crude (95% CI) . | HR, multivariable (95% CI)* . |
|---|---|---|
| Sex | ||
| Female | 2.76 (1.46-5.21) | 2.06 (1.07-3.95) |
| Male | 1.83 (1.03-3.26) | 2.40 (1.34-4.32) |
| Age, y | ||
| ≤60 | 17.41 (5.73-52.90) | 7.74 (2.12-28.29) |
| >60 to ≤70 | 1.14 (0.36-3.61) | 1.59 (0.50-5.14) |
| >70 to ≤80 | 1.35 (0.50-3.64) | 1.00 (0.36-2.78) |
| >80 | 2.65 (1.45-4.88) | 2.74 (1.48-5.08) |
| WHO-PF | ||
| 0-1 | 2.51 (1.63-3.48) | 2.62 (1.69-4.04) |
| >1 | ND | ND |
| Previous VTE | ||
| No | 2.36 (1.49-3.74) | 2.37 (1.50-3.76) |
| Yes | 1.05 (0.32-3.48) | 1.10 (0.32-3.83) |
| Second primary cancer | ||
| No | 1.68 (0.9-2.85) | 1.40 (0.82-2.39) |
| Yes | ND | ND |
| IgHV mutational status | ||
| Mutated | 2.11 (0.93-4.75) | 1.75 (0.76-4.02) |
| Unmutated | 2.07 (0.97-4.43) | 1.77 (0.82-3.81) |
| Not assessed | ||
| β2-microglobulin, mg/L | ||
| <4 | 2.02 (1.07-3.80) | 2.21 (1.16-4.21) |
| ≥4 | 1.44 (0.49-2.68) | 1.72 (0.73-4.04) |
| Not assessed | 2.89 (1.28-6.53) | 1.98 (0.85-4.60) |
Adjusted for all other variables in the table (second primary cancer after CLL diagnosis as time-varying exposure and age as age + age2).